Literature DB >> 12579094

The role of proinflammatory cytokines in lung ischemia-reperfusion injury.

Baiya Krishnadasan1, Babu V Naidu, Karen Byrne, Charles Fraga, Edward D Verrier, Michael S Mulligan.   

Abstract

OBJECTIVE: Proinflammatory cytokines are known to play roles in ischemia-reperfusion injury of the heart, kidney, small bowel, skin, and liver. Little is known about their roles in ischemia-reperfusion injury of the lung. This study was undertaken to define the role of 2 proinflammatory cytokines, tumor necrosis factor alpha and interleukin 1beta, in ischemia-reperfusion injury of the lung.
METHODS: Left lungs of male rats were rendered ischemic for 90 minutes and reperfused for up to 4 hours. Treated animals received anti-tumor necrosis factor alpha or anti-interleukin 1beta antibody before reperfusion. Increased vascular permeability in the lung was measured by using iodine 125-labeled bovine serum albumin. Neutrophil sequestration in the lung parenchyma was determined on the basis of activity. Bronchoalveolar lavage was performed to measure cell counts. Separate tissue samples were processed for histology, cytokine protein, and messenger RNA content by using Western blotting and the ribonuclease protection assay.
RESULTS: Animals receiving anti-tumor necrosis factor alpha and anti-interleukin 1beta demonstrated reduced injury compared with that seen in positive control animals (vascular permeability of 48.7% and 29.4% lower, respectively; P <.001). Vascular injury was reduced by 71% when antibodies to tumor necrosis factor alpha and interleukin 1beta were administered together. Lung neutrophil accumulation was markedly reduced among animals receiving anti-tumor necrosis factor alpha and anti-interleukin 1beta (myeloperoxidase content of 30.9% and 38.5% lower, respectively; P <.04) and combination blockade afforded even greater protection (52.4% decrease, P <.01). Bronchoalveolar lavage leukocyte content was also reduced by treatment with anti-tumor necrosis factor alpha, anti-interleukin 1beta, and combination treatment. Reductions in permeability, myeloperoxidase, and bronchoalveolar lavage leukocyte content also resulted in a decrease in a histologic injury. Finally, anti-tumor necrosis factor alpha and anti-interleukin 1beta treatment resulted in decreased messenger RNA expression for a number of early response and regulatory cytokines.
CONCLUSION: Tumor necrosis factor alpha and interleukin 1beta help regulate the development of lung ischemia-reperfusion injury. They appear to promote injury by altering expression of proinflammatory and anti-inflammatory cytokines and influencing tissue neutrophil recruitment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12579094     DOI: 10.1067/mtc.2003.16

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  34 in total

1.  Reduced-flow ex vivo lung perfusion to rehabilitate lungs donated after circulatory death.

Authors:  Jared P Beller; Matthew R Byler; Dustin T Money; William Z Chancellor; Aimee Zhang; Yunge Zhao; Mark H Stoler; Adishesh K Narahari; Alexander Shannon; J Hunter Mehaffey; Curtis G Tribble; Victor E Laubach; Irving L Kron; Mark E Roeser
Journal:  J Heart Lung Transplant       Date:  2019-09-18       Impact factor: 10.247

Review 2.  Lung transplantation: opportunities for research and clinical advancement.

Authors:  David S Wilkes; Thomas M Egan; Herbert Y Reynolds
Journal:  Am J Respir Crit Care Med       Date:  2005-07-14       Impact factor: 21.405

3.  The influence of lung ischemia-reperfusion injury on myocardium.

Authors:  Meng Shi; Jiechun Huang; Liewen Pang; Xiaotian Sun; Xianglin Chu; Rongrong Jang; Xiaolin Xu; Yiqing Wang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

4.  Clinical Risk Factors and Prognostic Model for Primary Graft Dysfunction after Lung Transplantation in Patients with Pulmonary Hypertension.

Authors:  Mary K Porteous; James C Lee; David J Lederer; Scott M Palmer; Edward Cantu; Rupal J Shah; Scarlett L Bellamy; Vibha N Lama; Sangeeta M Bhorade; Maria M Crespo; John F McDyer; Keith M Wille; A Russell Localio; Jonathan B Orens; Pali D Shah; Ann B Weinacker; Selim Arcasoy; David S Wilkes; Lorraine B Ware; Jason D Christie; Steven M Kawut; Joshua M Diamond
Journal:  Ann Am Thorac Soc       Date:  2017-10

5.  Extracorporeal membrane oxygenation: beneficial strategy for lung transplant recipients.

Authors:  Silvia R Cottini; Urs Wenger; Susanne Sailer; Paul A Stehberger; Reto A Schuepbach; Peter Hasenclever; Markus Wilhelm; Markus Béchir
Journal:  J Extra Corpor Technol       Date:  2013-03

Review 6.  Lung transplantation: infection, inflammation, and the microbiome.

Authors:  Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn
Journal:  Semin Immunopathol       Date:  2011-01-27       Impact factor: 9.623

Review 7.  Inflammasomes and IL-1 biology in the pathogenesis of allograft dysfunction.

Authors:  S Samuel Weigt; Vyacheslav Palchevskiy; John A Belperio
Journal:  J Clin Invest       Date:  2017-06-01       Impact factor: 14.808

8.  Differential toll-like receptor activation in lung ischemia reperfusion injury.

Authors:  Patrick Phelan; Heather E Merry; Billanna Hwang; Michael S Mulligan
Journal:  J Thorac Cardiovasc Surg       Date:  2015-02-28       Impact factor: 5.209

9.  Evaluation of early macrophage activation and NF-kappaB activity in pulmonary injury caused by deep hypothermia circulatory arrest: an experimental study.

Authors:  Jing-hao Zheng; Bo-tao Gao; Zu-ming Jiang; Xiao-qing Yu; Zhi-wei Xu
Journal:  Pediatr Cardiol       Date:  2009-12-03       Impact factor: 1.655

10.  Protection from pulmonary ischemia-reperfusion injury by adenosine A2A receptor activation.

Authors:  Ashish K Sharma; Joel Linden; Irving L Kron; Victor E Laubach
Journal:  Respir Res       Date:  2009-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.